Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Randomized, Controlled Trial

Authors
Cheol Whan LeeJung-Min AhnDuk-Woo ParkSoo-Jin KangSeung-Whan LeeYoung-Hak KimSeong-Wook ParkSeungbong HanSang-Gon LeeIn-Whan SeongSeung-Woon RhaMyung-Ho JeongDo-Sun LimJung-Han YoonSeung-Ho HurYun-Seok ChoiJoo-Young YangNae-Hee LeeHyun-Sook KimBong-Ki LeeKee-Sik KimSeung-Uk LeeJei-Keon ChaeSang-Sig CheongIl-woo SuhHun-Sik ParkDeuk-Young NahDoo-Soo JeonKi-Bae SeungKeun LeeJae-Sik JangSeung-Jung Park
Department
Dept. of Internal Medicine (내과학)
Issue Date
2014
Citation
Circulation, Vol.129(3) : 304-312, 2014
ISSN
0009-7322
Abstract
Background—The risks and benefits of long-term dual antiplatelet therapy remain unclear. Methods and Results—This is a prospective, multicenter, open-label, randomized comparison trial that was conducted in 24 clinical centers in Korea. In total, 5045 patients who received drug-eluting stents and were free of major adverse cardiovascular events and major bleeding for at least 12 months after stent placement were enrolled between July 2007 and July 2011. Patients were randomized to receive aspirin alone (n=2514) or clopidogrel plus aspirin (n=2531). The primary end point was a composite of death from cardiac causes, myocardial infarction, or stroke 24 months after randomization. At 24 months, the primary end point occurred in 57 aspirin-alone group patients (2.4%) and 61 dual-therapy group patients (2.6%) (hazard ratio, 0.94; 95% confidence intervals [CI], 0.66 to 1.35; P=0.75). The two groups did not differ significantly in terms of the individual risks of death from any cause, myocardial infarction, stent thrombosis, or stroke. Major bleeding occurred in 24 (1.1%) and 34 (1.4%) of the aspirin-alone group and dual-therapy group patients, respectively (hazard ratio, 0.71; 95% CI, 0.42 to 1.20; P=0.20). Conclusions—Among patients who were on 12-month dual antiplatelet therapy without complications, an additional 24 months of dual antiplatelet therapy versus aspirin alone did not reduce the risk of the composite end point of death from cardiac causes, myocardial infarction or stroke. Clinical Trial Registration Information—http://www.clinicaltrials.gov. Identifier: NCT01186146. Key Words: stent aspirin clopidogrel coronary
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35418
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
허승호
File in this Item
oak-aaa-00955.pdf(1.56 MB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE